NKTR | Nektar TherapeuticsNASDAQHealthcareCommon stock golden cross and death cross projections, cross tests and history

$37.76
+$0.81 (+2.19%)

Nektar Therapeutics (NKTR) is a NASDAQ-listed common stock that Cruxta has tracked for 50/200 crosses since 2018.

The 50 SMA has sat below the 200 on the daily since Oct 2026, with no cross projected inside the 30 bars Cruxta tracks. On both the daily and the 4-hour, price sits below the 50 and the 200; on the weekly it is between the two.

Timeframe summary

Daily as of 3 Nov 16:00 ET

Price
below both $37.76 vs 50 $54.23 / 200 $65.02
Projection
No cross projected
Test
No active test
Last cross
Death cross 13 Oct 2026 ยท projected 27 bars out

Weekly as of 30 Oct 16:00 ET

Price
between the two $38.87 vs 50 $62.16 / 200 $29.50
Projection
No cross projected
Test
No active test
Last cross
Golden cross week of 29 Dec 2025 ยท projected 29 bars out

4-hour as of 3 Nov 16:00 ET

Price
below both $37.76 vs 50 $40.04 / 200 $61.93
Projection
No cross projected
Test
No active test
Last cross
Death cross 29 Sep 2026 ยท projected 23 bars out

Cross history

24
crosses on record since 2018
12 golden12 death
Full cross history โ†’
CrossedDirectionTimeframeProjectedCross test
13 Oct 2026Death steepdaily27 bars outNot tested
29 Sep 2026Death4-hour23 bars outNot tested
24 Aug 2026Golden4-hour20 bars out2 bar cross test
11 Jun 2026Death4-hour29 bars outNot tested
27 Feb 2026Golden4-hour29 bars outNot tested

About NKTR

ExchangeNASDAQ
InstrumentCommon stock
Median $ volume, 60 d$49M
4-hour coverageYes, since Oct 2025
History on recordSince 2018
SectorHealthcare
Cap bandmid

Cruxta · 50/200 moving-average crosses on US equities. Recorded crosses are observations. Projected crosses are projections, not advice.